

CURRICULUM VITAE

Rhonda M. Cooper-DeHoff, Pharm D, MS, FAHA

Address: Residence - 6303 NW 93rd Terrace
Gainesville, FL 32653

Office - Department of Pharmacotherapy and Translational
Research
College of Pharmacy
University of Florida
PO Box 100486
Gainesville, FL 32610-0486

Email - dehoff@cop.ufl.edu

Telephone: Residence - (352) 335-4451
Office - (352) 273-6184
Fax - (352) 273-6121

Place of Birth: Anaheim, California
Date of Birth: February 1, 1960
Citizenship: USA
Marital Status: Married

Present Position: Associate Professor
Department of Pharmacotherapy and Translational Research
College of Pharmacy

Joint Faculty Appointment in:
Division of Cardiovascular Medicine
Department of Medicine
College of Medicine

University of Florida

EDUCATION

2007	University of Florida	MS in Medical Science with a Concentration in Clinical Investigation
1986	University of California School of Pharmacy San Francisco, California	Doctor of Pharmacy
1982	University of California Revelle College San Diego, California	Gen. Biology B.A.

POST GRADUATE TRAINING

- 2005-2007 University of Florida College of Medicine, Gainesville, FL, Fellow in the Advanced Postgraduate Program in Clinical Investigation (APPCI), funded by the NIH Clinical Research Curriculum Award (K30)
- 2006 American Heart Association, Fellowship
32nd Ten-day Seminar on the Epidemiology and Prevention of Cardiovascular Disease
- 1986-1987 University of California, San Francisco, Residency in Clinical Pharmacy

BOARD CERTIFICATION

- Licentiate in Pharmacy, California (inactive)
Licentiate in Pharmacy, Florida (current)

PROFESSIONAL POSITIONS

- Mar 2009-Present Associate Professor
University of Florida, College of Pharmacy
Department of Pharmacotherapy and Translational Research
- July 2008-Feb 2009 Research Associate Professor
University of Florida, College of Medicine
Division of Cardiovascular Medicine
- Sept. 1999-Jun 2008 Research Assistant Professor
University of Florida, College of Medicine
Division of Cardiovascular Medicine
- Sept. 1999-Feb 2009 Associate Director, Clinical Trials Program
University of Florida, College of Medicine
Division of Cardiovascular Medicine
Gainesville, FL
- Activities include the management of day to day operations of the cardiovascular clinical trials program, and the supervision of the research coordinators. Other responsibilities include the organization and management of the regulatory department for the clinical trials program.
- 1997-2004 Director, INVEST Pharmacy Coordinating Center
University of Florida, College of Medicine
Division of Cardiology
Gainesville, FL
- Activities include the oversight of medication dispensing for 22,000 national and international patients enrolled in the INVEST trial.
- 1987-1999 Coordinator, Investigational Drug Service
Shands Hospital at the University of Florida
Gainesville, Florida
Supervisor: Alan Knudsen, MS

Activities include developing and implementing an investigational drug service (IDS) in a large teaching institution. The IDS now controls medications for 390 different studies in both the inpatient and outpatient area. The IDS provides necessary drug and study information to all health care professionals and patients involved with the studies. Additionally, clinical research protocols are designed and written for the hospital by the IDS. A software program designed to control investigational drug data and inventory was developed here and is now marketed.

- 1994-1997 Director, Pharmacy Practice Residency
Shands Hospital at the University of Florida
Gainesville, Florida
- Coordinate and facilitate the pharmacy practice residency at Shands Hospital, including recruiting, precepting, and overseeing the program.
- 1992-1998 Clinical Trials Program Liaison
University Hospital Consortium's Clinical Practice Advancement Center
(formerly Technology Advancement Center)
Receive information about new clinical trials, and contact investigators who might be interested in conducting the trials.
- 1982-1987 Laboratory Assistant II
UCSF Drug Studies Unit
School of Pharmacy
Director: Roger L. Williams, M.D.
Activities include performing EKG's, blood drawing, sample processing, controlling and dispensing investigational drugs.

AWARDS AND HONORS

- 2009 Featured Poster Award
American Society of Hypertension, 24th Annual Scientific Meeting and Exposition, San Francisco, California
- 2009 ASHP Foundation Pharmacy Resident Practice-Based Research Grant Program Peer Review
- 2008 Clinical Science Award
The Consortium for Southeastern Hypertension Control (COSEHC), 15th Annual National Scientific Sessions, Baltimore, Maryland
- 2008 Vascular Biology / Blood Pressure Regulation
American Heart Association Peer Review, Committee R2
- 2007 Fellow, American Heart Association (FAHA.) and Council for High Blood Pressure Research.
- 2001 New Investigator Award
American Heart Association, Council on Basic Cardiovascular Sciences, Seattle, Washington
- 1988 Roche Award for Outstanding Research Affecting Patient Care

1987 Outstanding Young Women of America

1986 Outstanding Student Service Award
University of California, San Francisco
School of Pharmacy

COMMITTEE MEMBERSHIPS

2009-Present Institutional Review Board, University of Florida

2007-present Nurse Education Committee, American College of Cardiology

2007-present APPCI Advisory Committee, University of Florida

1987-2004 Institutional Review Board, University of Florida

1989-1999 General Clinical Research Center Scientific Advisory Committee ,
University of Florida

1991-1995 Shands Hospital Biotechnology Committee (Subcommittee of Pharmacy
and Therapeutics Committee)

TEACHING EXPERIENCE

Fall 2008 GMS 7039, Intro to Clinical Translational Research
Panel participant: "How I Got Funded"

Fall 2006, 2007 GMS 6181, Intro to Clinical Translational Research
"Out into the Community and Back to the Bench"

2006-2007 PHA 56**, Clinical Pharmacogenomics
"Ethical Conduct of Human Subjects Research"

2000-2003 Department of Medicine
Resident Rotation Preceptor
Cardiovascular Research

1995-1999 Basic and Clinical Research Course for Physicians and Fellows

1987-1999 Contemporary Pharmacy Systems for Pharm.D. Students
University of Florida, College of Pharmacy

1986-1987 Clinical Pharmacy Preceptor
University of California
School of Pharmacy
San Francisco, California

Supervised Clinical Pharmacy students who were completing their clerkship rotations in the hospitals and clinics at UCSF and SFGH. Assisted with organizing the course for the Clinical Pharmacy students, completed student evaluations, and held conferences for the students.

RESEARCH SUPPORT AND PROJECTS

Extramural Funding -

National Institutes of Health, NHLBI Resequencing and Genotyping Service Award via the J. Craig Venter Institute. Awarded May 2008. In kind resequencing valued at ~\$115,000. Understanding the Relationship of Transcription Factor 7-like Gene (*TCF7L2*) Polymorphisms and Incidence of Diabetes in an Ethnically Diverse Hypertensive Heart Disease Population. **Rhonda Cooper-DeHoff, Pharm D.** – Principal Investigator

National Institutes of Health, K23 HL086558-01, January 2007-January 2012. \$672,170 Metabolic Effects of Antihypertensive Responses (MEAD). **Rhonda Cooper-DeHoff, Pharm D.** – Principal Investigator

Cleveland Clinic and Pfizer, 02/06/07-12/29/07, \$135,306.25, *Prospective Randomized Evaluation of Celecoxib Integrated Safety, vs. Ibuprofen Or Naproxen-PRECISION*, Carl Pepine, M.D. and **Rhonda Cooper DeHoff, Pharm D.** - Co-Investigator

National Institutes of Health, U01 GM074492 (PI: J.A. Johnson), August 2005 – July 2010, \$11,149,034 Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR). **Rhonda Cooper-DeHoff, Pharm D.** – Co-Investigator

National Institutes of Health. 9/2003 – 8/2007, \$2,515,086. Hypertension Pharmacogenetics. Julie Johnson, PharmD, Carl Pepine, M.D., **Rhonda Cooper-DeHoff, Pharm.D.** – Co-Investigator

Pfizer Pharmaceuticals. 8/2001–2/2008, \$153,437. Effect of Sildenafil on Coronary and Systemic Vascular Function in women with chest pain. Carl J. Pepine, M.D.- PI, **Rhonda Cooper DeHoff, Pharm.D.** – Co-Investigator

Intramural Funding -

University of Florida, Clinical and Translational Science Institute. 10/2008-10/2009, \$17,500. PPAR γ Expression in Key Metabolic Organ Systems is Modulated by Treatment with Thiazide Diuretics and ACE Inhibition. **Rhonda Cooper-DeHoff, Pharm D.** – Principal Investigator

University of Florida, 2/2004 to 2/2007 WISE / Women Take Heart Collaboration. **Rhonda Cooper-DeHoff, Pharm.D.** – Principal Investigator

Completed Research

Abbott Laboratories. 3/1997 to 12/2006, \$36,086,562. International VErapamil-trandolapril Study (INVEST) is a randomized, Controlled Clinical Trial Comparing a Calcium Antagonist Treatment Strategy with a Non-calcium Antagonist Treatment Strategy for the Control of Hypertension and Angina in a Primary Care Ambulatory Patient Population. Carl J. Pepine, M.D. - PI, **Rhonda Cooper-DeHoff, Pharm.D.** - Co-Investigator

University of Florida, 1/1996 to 1/2007. Evaluation of Lewis Phenotype as a Risk Factor for Coronary Artery Disease. **Rhonda Cooper-DeHoff, Pharm.D.**

Pfizer Pharmaceuticals. 4/2002 to 10/2006, \$206,420. A pilot study to determine the effect of Celecoxib 400mg and 800mg on markers of inflammation in patients with hypertension & coronary artery disease. **Rhonda Cooper-DeHoff, Pharm.D.** – Principal Investigator

Perry E. Foote Outcomes Research Small Grant Program, 7/2001 to 5/2004, \$10,000. A pilot study to determine the effect of Celecoxib 400mg and 800mg on markers of inflammation in

patients with hypertension and coronary artery disease. **Rhonda Cooper-DeHoff, Pharm.D.** – Principal Investigator

Drug Use Evaluation of DNase 1994 During the First 6 Months of Use. **Rhonda Cooper, Pharm.D.**, and Sherry Ingram, Pharm.D.

Cost of Hospital Admissions as a Result of Phenytoin Adverse Drug Reactions. 1993 Lisa Daley, Pharm.D., **Rhonda Cooper, Pharm.D.**, and Randy Hatton, Pharm.D.

Prospective, Controlled, Third Party Blind, Randomized, Multi-center Comparison of the Safety and Efficacy of Ciprofloxacin plus Metronidazole (IV only and IV/PO) with that of Imipenem-Cilastatin for the Treatment of Patients with Intra-abdominal Infections. 1991 Stephen Vogel, M.D., Larry Aull, Pharm.D., and **Rhonda Cooper, Pharm.D.**

The Efficacy of Indomethacin Compared to Ibuprofen and Acetaminophen-diphenhydramine-hydrocortisone in the Treatment of Shaking Chills Associated with Amphotericin B. 1990 Stan Reents, Pharm.D., **Rhonda Cooper, Pharm.D.** and Vipul Singh, M.D.

An Assessment of the Readability and Comprehension of IRB Approved Informed Consent Forms. 1989 Rebecca Murgatroyd, Pharm.D. and **Rhonda Cooper, Pharm.D.**

A Multi-center, Open Label, Variable Dose Evaluation of Morphine Sustained Release Suspension Administered for 3 Days in the Treatment of Cancer Pain. 1988 **Rhonda M. Cooper, Pharm.D.** and David Oblon, M.D.

A Retrospective Analysis of the Effect of Investigational Studies on Current Ceftazidime Usage at Shands Hospital. 1988 **Rhonda M. Cooper, Pharm.D.**

Utilization of and Satisfaction with a New Investigational Drug Service. 1987 **Rhonda M. Cooper, Pharm.D.** and Becky Coleman, Pharm.D.

The Pharmacokinetics of Ketoprofen in the Elderly. 1987 **Rhonda M. Cooper, Pharm.D.**, Nancy Sambol, Pharm.D., and Roger L. Williams, M.D.

PROFESSIONAL OFFICES AND APPOINTMENTS

1987-1989 Secretary, North Central Florida Society of Hospital Pharmacists

1986-1987 Western Regional Alumni Director
Phi Delta Chi Pharmaceutical Fraternity

MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS

Phi Kappa Phi Honor Society
American Society of Hypertension
American Heart Association
American College of Cardiology
Florida Society of Hospital Pharmacists
North Central Florida Society of Hospital Pharmacists

PUBLICATIONS

Articles in Refereed Journals:

1. **Cooper RM.** Potassium Iodide for Radiation Exposure. *Drug Intelligence and Clinical Pharmacy.* 1988; 22: 33-34.
2. Huang D, Harman E, Friedman B, Tanaka W, **Cooper RM**, Hendeles L. Effect of a leukotriene synthesis inhibitor (MK-886) on the early and late asthmatic response. *Chest* 1990;98:50S.
3. Hendeles L, Davison D, Blake K, Harman E, **Cooper RM**, Margolskee D. Leukotriene D₄ is an important mediator of antigen-induced bronchoconstriction: Attenuation of dual response with MK-571, a specific LTD₄ receptor antagonist. *J Allergy Clin Immunol* 1990;85:197.
4. Murgatroyd RJ, **Cooper RM.** Readability of informed consent forms. *Am J of Hosp Pharm* 1991;48:2651-2652.
5. Pepine CJ, Handberg E, Marks RG, Conlon M, **Cooper-DeHoff, RM**, Volkens P, Zelles P. Rationale and design of the INternational VERapamil SR/Trandolapril STudy (INVEST): An internet-based randomized trial in coronary artery disease patients with hypertension. *J Am Coll Cardiol* 1998;32(5):1228-37.
6. Grant MB, Mames RN, Fitzgerald C, Hazariwala KG, **Cooper-DeHoff R**, Caballero S, Estes KS. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. *Diabetes Care* 2000;23(4):504-509.
7. **Cooper-DeHoff RM**, Handberg E, Heissenberg, C, Johnson, K. Electronic prescribing via the internet for a coronary artery disease and hypertension megatrial. *Clin Cardiol* 2001;24(11):V14-V16.
8. Conti CR, **Cooper-DeHoff RM.** How will INVEST and other hypertension trials change clinical practice? *Clin Cardiol* 2001;24(11):V24-V29.
9. Pepine CJ, **Cooper-DeHoff RM**, Weiss RJ, Koren M, Bittar N, Thadani U, Minkwitz MC, Michelson EL, and Hutchinson HG. Comparative Efficacy and safety of nisoldipine and amlodipine (CESNA-II) study investigators. Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. *Am J Cardiol* 2003;91(3):274-279.
10. Pepine CJ, Handberg EM, **Cooper-DeHoff RM**, Marks RG, Kowey P, Messerli FH, Mancina G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The INternational VERapamil-Trandolapril STudy (INVEST). *JAMA* 2003;290(21):2805-2816.
11. Pepine CJ, **Cooper-DeHoff RM.** Cardiovascular therapies and risk for development of diabetes. *J Am Coll Cardiol* 2004;44(3):509-512.
12. **Cooper-DeHoff RM**, Handberg EM, Cohen J, Kowey P, Messerli F. Characteristics of contemporary patients with hypertension and coronary artery disease. *Clin Cardiol.* 2004;27(10):571-576.
13. Bakris GL, Gaxiola E, Messerli FH, Mancina G, Erdine S, **Cooper-DeHoff RM**, Pepine CJ; INVEST Investigators. Clinical outcomes in the diabetes cohort of the INternational VERapamil SR-trandolapril STudy. *Hypertension* 2004;44(5):637-42.
14. Zineh I, **Cooper-DeHoff RM**, Wessel TR, Arant CB, Sleight P, Geiser EA, Pepine CJ. Global differences in blood pressure control and clinical outcomes in the INternational VERapamil SR-trandolapril STudy (INVEST). *Clin Cardiol* 2005;28(7):321-328.
15. Elliott WJ, Hewkin AC, Kupfer S, **Cooper-DeHoff RM**, Pepine CJ. A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients. *J Clin Hypertension* 2005;7(11):654-663.

16. **Cooper-DeHoff RM**, Pepine CJ. Editorial: Ranolazine is associated with cardiovascular and metabolic improvement: A win-win for patients with diabetes. *Eur Heart J* 2006;27(1):5-6.
17. Pepine CJ, Kowey PR, Kupfer S, Kolloch RE, Benetos A, Mancina G, Coca A, **Cooper-DeHoff RM**, Handberg EM, Gaxiola E, Sleight P, Conti CR, Hewkin AC, Tavazzi L. Predictors of adverse outcomes among patients with hypertension and coronary artery disease. *J Am Coll Cardiol* 2006;47(3):547-551.
18. **Cooper-DeHoff RM**, Aranda JM, Gaxiola E, Cangiano JL, Garcia-Barreto D, Conti CR, Hewkin A, Pepine CJ. Blood pressure control and cardiovascular outcomes in high risk Hispanic patients – Findings from the International Verapamil SR – Trandolapril Study. *Am Heart J* 2006;151(5):1072-79.
19. **Cooper-DeHoff RM**, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, Pepine CJ. Predictors of Development of Diabetes Mellitus in Patients with Coronary Artery Disease Taking Antihypertensive Medications (Findings from the INternational VERapamil SR-Trandolapril Study [INVEST]). *Am J Cardiol* 2006, 98:890-894.
20. Epstein, BJ and **Cooper-DeHoff, RM**. Effect of Ramipril on the Incidence of Diabetes – Letter to the Editor. *N Engl J Med*. 2007;356:523.
21. Bakris GL, **Cooper-DeHoff RM**, Zhou Q, Kupfer S, Champion A, Pepine CJ, for the INVEST Investigators. Dual Therapy in Hypertensive Patients with Coronary Artery Disease: The Role of Calcium Channel Blockers and B-Blockers. *Am. J. Cardiovasc. Drugs*. 2007; 7 Suppl. 1: 25-29.
22. Langaee TY, Gong Y, Yarandi HN, Katz DA, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Association of CYP3A5 Polymorphisms with Hypertension and Antihypertensive Response to Verapamil. *Clinical Pharmacology & Therapeutics*. 2007. Vol. 81, No. 3, 386-391.
23. **Cooper-DeHoff RM**, Zhou Q, Gaxiola E, Cangiano JL, Garcia-Barreto D, Handberg E, Pepine CJ. Influence of Hispanic Ethnicity on Blood Pressure Control and Cardiovascular Outcomes in Women with CAD and Hypertension: Findings from INVEST. *Journal of Women's Health*, 2007;16:632-640.
24. Brunner M, **Cooper-DeHoff RM**, Gong Y, Karnes JH, Langaee TY, Pepine CJ, Johnson JA. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/ Trandolapril [INVEST] Study). *Am J Cardiol* 2007;99:1549-1554.
25. Beitelshes AL, Gong Y, **Cooper-DeHoff RM**, Burt L, Stauffer LA, Pepine CJ, Johnson JA.. KCNMB1 genotype influences response to verapamil. SR and adverse outcomes in the INternational VERapamil SR/Trandolapril Study (INVEST). *Pharmacogenetics and Genomics* 2007;17:719-729.
26. Uretsky S, Messerli FH, Bangalore S, Champion A, **Cooper-DeHoff RM**, Zhou Q, Pepine, CJ. Obesity Paradox in Patients with Hypertension and Coronary Artery Disease. *The American Journal of Medicine*. 2007. 120;10: 863-870.
27. **Cooper-DeHoff RM**, Pepine CJ. Metabolic Syndrome and Cardiovascular Disease: Challenges and Opportunities. *Clinical Cardiol* 2007; 30, 593-597.
28. Coca A, Messerli FH, Benetos A, Zhou Q, Champion A, **Cooper-DeHoff RM**, Pepine CJ. Predicting Stroke Risk in Hypertensive Patients with Coronary Artery Disease: A Report from the INVEST. *Stroke*, 2008;39:343-348.
29. Kolloch R, Legler UF, Champion A, **Cooper-DeHoff RM**, Handberg E, Zhou Q, and Pepine CJ. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VERapamil-SR/trandolapril Study (INVEST) *Eur Heart J*. 2008;29:1327-34.
30. Pacanowski MA, Zineh I, Li H, Johnson BD, **Cooper-DeHoff RM**, Bittner V, McNamara DM, Sharaf BL, Bairey Merz CN, Pepine CJ, Johnson JA. Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. *J Transl Med*. 2008. 6:1-11.

31. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, **Cooper-DeHoff RM**, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ. Postmenopausal Women with a History of Irregular Menses and Elevated Androgen Measurements at High Risk for Worsening Cardiovascular Event-Free Survival: Results from the National Institutes of Health--National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation. *J Clin Endocrinol Metab.* 2008 Apr;93(4):1276-84.
32. Gerhard T, Gong Y, Beitelshes AL, Mao X, Lobmeyer MT, **Cooper-DeHoff RM**, Langaee TY, Schork NJ, Shriver MD, Pepine CJ, Johnson JA; INVEST Investigators. Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENETic Substudy of the INternational VERapamil SR-trandolapril STudy (INVEST-GENES). *Am Heart J.* 2008 Aug;156(2):397-404.
33. Pacanowski MA, Gong Y, **Cooper-DeHoff RM**, Schork N, Shriver M, Langaee T, Pepine CJ, Johnson J. beta-Adrenergic Receptor Gene Polymorphisms and beta-Blocker Treatment Outcomes in Hypertension. *Clin Pharmacol Ther.* 2008;84:715-21.
34. **Cooper-DeHoff RM**. Thiazide Induced Dysglycemia – It's Time To Take Notice. *Exp Rev of Card Ther* 2008;6:1291-1294.
35. Johnson AD, Gong Y, Wang D, Langaee TY, Shin J, **Cooper-DeHoff RM**, Schork NJ, Bindley P, Pepine CJ, Johnson JA, Sadee W. Pormoter polymorphisms in ACE (angiotensin-I converting enzyme) associated with clinical outcomes in hypertension. *Clin Pharmacol Ther* 2009;85:36-44
36. **Cooper-DeHoff RM**, Pacanowski MA, Pepine, CJ. Cardiovascular Therapies and Associated Glucose Homeostasis: Implications across the Dysglycemia Continuum. *J Am Coll Cardiol* 2009;53:S28-34.
37. Denardo SJ, Messerlli FH, Gaxiola E, Aranda JM, **Cooper-DeHoff RM**, Handberg EM, Gong Y, Champion A, Zhou Q, Pepine, CJ. Characteristics and Outcomes of Revascularized Patients with Hypertension – An International Verapamil SR-Trandolapril Substudy. *Hypertension.*2009; 53(4):624-30.
38. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, **Cooper-DeHoff RM**, Gums J, Curry RW, Gong Y, Beitelshes AL, Schwartz G, Turner ST. Pharmacogenomics of Antihypertensive Drugs: Rationale and Design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *Am Heart J* 2009;157:442-449.
39. Pacanowski MA, Zineh I, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Genetic and Pharmacogenetic Associations Between NOS3 Polymorphisms, Blood Pressure, and Cardiovascular Events in Hypertension. *Am J Hypertens*, 2009, epub ahead of print <http://www.nature.com/doifinder/10.1038/ajh.2009.81>
40. Gulati M, **Cooper-DeHoff RM**, McClure C, Johnson BD, Shaw LJ, Handberg EM, Zineh I, Kelsey SF; Arnsdorf MF, Black HR, Pepine CJ, Bairey Merz CN. Adverse Cardiovascular Outcomes In Women with Nonobstructive Coronary Artery Disease: A Report From The National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study and The St James Women Take Heart (WTH) Project. *Arch Int Med* 2009;169: 843-850.
41. Gong Y, Handberg EM, Gerhard T, **Cooper-DeHoff RM**, Ried D, Johnson JA, Pepine CJ. Systolic Blood Pressure and Subjective Well-Being in Patients with Coronary Artery Disease. *Clinical Cardiology* 2009, In Press.
42. Karnes JH, **Cooper-DeHoff RM**. Antihypertensive Medications: Benefits of BP Lowering and Hazards of Metabolic Effects. *Exp Rev of Card Ther* 2009, In Press.
43. Beitelshes AL, Navara H, Wang D, Gong Y, Wessel J, Moss J, Langaee TY, Cooper-DeHoff RM, Sadee W, Pepine CJ, Schork NJ, Johnson JA. CACNA1C gene Polymorphisms, Cardiovascular Disease Outcomes and Treatment Response. *Circ Genetics* 2009. In Press.
44. Pauly DF, Johnson DB, Anderson RD, Handberg EM, Smith KM, **Cooper-DeHoff RM**, Sopko G, Sharaf BM, Kelsey SF, Bairey Merz CN, Pepine CJ. In Women with Symptoms of Cardiac Ischemia, Non-Obstructive Coronary Arteries and Microvascular Dysfunction,

ACE Inhibition is Associated with Improved Microvascular Function: A Double-blind Randomized Substudy from the NHLBI Women's Ischemia Syndrome Evaluation (WISE). *Eur Heart J*, 2009, submitted.

45. **Cooper-DeHoff RM**, Wen S, Beitelshes AL, Zineh I, Gums JG, Turner ST, Gong Y, Hall K, Parekh V, Chapman AB, Boerwinkle E, Johnson JA. Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated with Antihypertensive Medications. *Diabetes Care*, 2009, submitted.

ABSTRACTS:

Peer Reviewed abstract presented at national and international meetings

1. Pepine CJ, Conlon M, Handberg-Thurmond E, Marks RG, **Cooper-DeHoff RM**, Kolb HR. A 'paper-less' study on optimal treatment strategies for hypertension and CAD: Pilot phase data from the INternational VERapamil-trandolapril STudy (INVEST). *J Am Coll Cardiol* 1998;31(2):211A.
2. **Cooper-DeHoff RM**, Handberg EM, Marks RG, Conlon M, Kolb HR, Bristol H, and Pepine CJ for the INVEST Investigators. Control of blood pressure in a population of women with hypertension and CAD using an Internet-based electronic prescribing system. *Am J Hypertension* 2000;13(4):117A.
3. **Cooper-DeHoff RM**, Handberg EM, Bristol HA, Kolb HR, Gaxiola E, Cangiano J, Pepine CJ. Characteristics and blood pressure responses of 6,057 Hispanic hypertensive patients with coronary artery disease enrolled in the INVEST. *J Am Coll Cardiol* 2001;37(2):216A.
4. **Cooper-DeHoff RM**, Handberg EM, Bristol H, Kolb M, Keltai R, Kolloch S, Erdine G, Mancica C, Pepine CJ. A comparison of European vs non-European hypertensive patients with co-existing coronary artery disease: An analysis from the total randomized sample of the INVEST. *J of Hypertension* 2001;19(S2):S189.
5. **Cooper-DeHoff RM**, Handberg EM, Bristol H, Kolb H, Pepine CJ. Blood pressure control in a cohort of patients with diabetes and ischemic heart disease. American Heart Association Scientific Conference on Molecular, Integrative, and Clinical Approaches to Myocardial Ischemia 2001;P125.
6. **Cooper-DeHoff RM**, Handberg EM, Bristol HA, Pepine CJ, for INVEST Investigators. Ethnicity and blood pressure control in patients with diabetes and coronary artery disease. *Am J Hypertension* 2002;15(4):194A.
7. **Cooper-DeHoff RM**, Handberg EM, Bristol HA, Kolb HR, Cangiano J, Cohen JD, Erdine S, Gaxiola E, Keltai M, Kolloch R, Kowey P, Mancica G, Messerli F, Pepine CJ for INVEST Investigators. Characteristics predicting blood pressure responses in 22,599 patients with hypertension and coronary artery disease. *Am J Hypertension* 2002;15(4):116A.
8. **Cooper-DeHoff RM**, Bristol HA, Pepine CJ. Systolic blood pressure control in diabetics and nondiabetics with hypertension and coronary artery disease. *J Am Coll Cardiol* 2003;41(6):320A.
9. **Cooper-DeHoff, RM**, Bristol HA, Pepine CJ. Ethnic differences in systolic blood pressure control in hypertensive patients with coronary artery disease. *Am J Hypertension* 2003;16(5):27A.
10. **Cooper-DeHoff, RM**, Gaxiola E, Cangiano JL, Barreto D, Conti, CR, Pepine CJ. Blood pressure reduction and CV outcomes in hypertensive Hispanics, Blacks and Caucasians with coronary artery disease: The International Verapamil Trandolapril Study. *Circulation*. 2003;108(17): IV-450.
11. **Cooper-DeHoff RM**, Bakris G, Cohen J, Messerli F, Erdine S, Bristol H, Pepine CJ. Reduced risk of new onset diabetes in hypertensive coronary artery disease patients treated with a calcium antagonist vs. a beta blocker regimen: the International Verapamil/Trandolapril Study. *Circulation* 2003;108(17):IV-750.
12. Messerli FH, **Cooper-DeHoff RM**, Kupfer SR, Pepine CJ. Lean Body Mass is Associated with the Highest Incidence of Mortality and Cardiovascular Morbidity in Hypertensive Patients with Coronary Artery Disease: Results from the INternational VERapamil SR/trandolapril STudy (INVEST) Presented at 1st Congress, World Congress on the Insulin Resistance Syndrome, 2003.
13. Cohen JD, **Cooper-DeHoff RM**, Bakris GL, Conti R, Pepine CJ. Increased systolic blood pressure is associated with new diabetes in hypertensive patients with coronary artery disease. *Diabetes* 2004;53(2):A85.

14. **Cooper-DeHoff, RM**, Kolloch R, Messerli FH, Handberg EM, Pepine CJ. Blood pressure control, angina episodes, and cardiovascular outcomes in patients with ischemia: the International Verapamil-Trandolapril Study. *J Am Coll Cardiol* 2004;43(5):483A.
15. Mancia G, **Cooper-DeHoff RM**, Hewkin AC, Kupfer SR, Pepine CJ. Association of BP control and frequency of mortality and CV morbidity in hypertensive patients with CAD: the INternational VERapamil SR-trandolapril STudy. *Am J Hypertension* 2004;17:116A.
16. Mancia G, Hewkin A, **Cooper-DeHoff R**, Champion A, Pepine C. Uncontrolled blood pressure is risk equivalent to diabetes and prior myocardial infarction for cardiovascular outcomes: The INternational VERapamil SR-trandolapril STudy. *Eur Heart J* 2004;25:662.
17. Zineh I, Ma CX, Wessel TR, Arant CB, **Cooper-DeHoff R**, Pauly DF, McGorray SP, Bairey Merz CN, Pepine CJ, Johnson JA. Influence of adrenergic system polymorphisms and nongenetic factors on obstructive coronary artery disease (CAD) in women: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). *Circulation* 2004;110(17):III-353.
18. Pepine CJ, Hewkins A, **Cooper-DeHoff RM**, Champion A, Mancia G. Outcome benefits of BP control in older CAD patients with hypertension: The INternational VERapamil SR-trandolapril STudy (INVEST). *Circulation* 2004;110(17):III-731.
19. **Cooper-DeHoff RM**, Aranda JM Jr., Handberg EM, Zhou Q, Pepine CJ. Blood pressure control and cardiovascular outcomes in Hispanic women with coronary artery disease hypertension: Findings from the International Verapamil-Trandolapril Study. *Circulation* 2005;111(4):E76.
20. Gong Y, Beitelshees AL, Stauffer L, Gaston K, Sloan A, Yarandi HN, Langaee TY, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Beta 2-adrenergic receptors (B2AR) polymorphism and anti-hypertension response to beta-blocker therapy in the INVEST trial. *Clin Pharmacol Ther* 2005;77(2):P22. Presented as a poster presentation at the American Society for Clinical Pharmacology and Therapeutics 106th Annual Meeting, Orlando, FL, March 2005.
21. Beitelshees AL, Gong Y, **Cooper-DeHoff RM**, Moss JI, Pepine CJ, Johnson JA. Variable blood pressure response to verapamil by KCNMB1 genotype. *Clin Pharmacol Ther* 2005;77(2):P97. Presented as an oral presentation at the American Society for Clinical Pharmacology and Therapeutics 106th Annual Meeting, Orlando, FL, March 2005.
22. Pepine C, Coca A, Messerli F, Benetos A, Zhou Q, Champion A, **Cooper-DeHoff RM**. Stroke risk in hypertensive patients with coronary artery disease: The International VERapamil SR-trandolapril STudy (INVEST). *J Am Coll Cardiol* 2005;45(3):424A.
23. Elliott W, Hewkin A, Champion A, **Cooper-DeHoff RM**, Pepine CJ. E-prescription database analysis supports use of combination therapy in hypertensive patients with CAD in INVEST. *Am J Hypertension* 2005;18:58A.
24. **Cooper-DeHoff RM**, Qian Zhou, Pepine CJ. BP control and CV outcomes in Hispanic and Nonhispanic women with CAD and hypertension: Findings from INVEST. *Am J Hypertension* 2005;18:104A.
25. Messerli F, **Cooper-DeHoff RM**, Champion A, Hewkin A, Pepine CJ. Lean body mass is associated with increased incidence of mortality and cardiovascular morbidity in hypertensive patients with coronary artery disease: The INternational VERapamil-SR-trandolapril STudy (INVEST). *Am J Hypertension* 2005;18:148A.
26. **Cooper-DeHoff RM**, Gaxiola E, Zhou Q, Handberg EM, Pepine CJ. Verapamil SR-based antihypertensive strategy reduces risk of new onset diabetes in Hispanic patients with coronary artery disease and hypertension: Findings from the INternational VERapamil SR-trandolapril STudy (INVEST). *J Am Diabetes Assoc* 2005;54(1):1047P.
27. Gerhard T, Gong Y, Beitelshees AL, Lobmeyer M, Schiefelbein L, Langaee TY, **Cooper-DeHoff RM**, Johnson JA. Association between CV outcomes, diuretic use and the α -

- adducin gene: Results from the International Verapamil SR-trandolapril Study (INVEST). *Circulation* 2005;112(17):II-608.
28. Shaw L, Johnson B, **Cooper-DeHoff RM**, Bittner V, Kelsey S, Reis S, Sopko G, Pepine C, Sharaf B, Bairey Merz N. Importance of socioeconomic status as a predictor of cardiovascular outcome in women. *Circulation* 2005;112(17):II-808.
 29. Langaee TY, Yarandi HN, Katz DA, **Cooper-DeHoff RM**, Kehoe JM, Klocman AS, Pepine CJ, Johnson JA. Differences in verapamil response between CYP3A5 genotypes. *Clin Pharmacol Ther* 2006;79(2):P12.
 30. Brunner M, Karnes JH, Gong Y, Langaee TY, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Association of angiotensin II type I receptor (AGTR1) 1166A>C polymorphism with blood pressure response to ace inhibitor in a subgroup of patients of the International Verapamil CR/trandolapril Study (INVEST). *Clin Pharmacol Ther* 2006;79(2):P14.
 31. Gong Y, Beitelshes AL, Stauffer LA, Langaee TY, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Beta adrenergic receptors polymorphisms are associated with response to beta-blocker therapy in the International Verapamil SR-Trandolapril Study (INVEST). *Clin Pharmacol Ther* 2006;79(2):P30.
 32. Beitelshes AL, Gong Y, **Cooper-DeHoff RM**, Burt L, Stauffer LA, Pepine CJ, Johnson JA. KCNMB1 genotype associated with cardiovascular outcomes in the International Verapamil SR/trandolapril Study (INVEST). *Clin Pharmacol Ther* 2006;79(2):P41, 2006.
 33. Johnson JA, Karnes JH, Brunner M, Gong Y, Langaee TY, **Cooper-DeHoff RM**, Pepine CJ. Lack of association of the angiotensin II type I receptor (AGTR1) 1166A>C polymorphism with cardiovascular and cerebrovascular outcomes in a subgroup of patients of the International Verapamil SR/trandolapril Study (INVEST). *Clin Pharmacol Ther* 2006;79(2):P43.
 34. Handberg E, Gong Y, **Cooper-DeHoff RM**, Ried LD, Pepine CJ. Can an assessment of subjective well being predict outcomes in patients with hypertension and coronary artery disease? A report from the International Verapamil-SR/Trandolapril Study. *J Am Coll Cardiol* 2006; 47(4):300A.
 35. **Cooper Dehoff RM**, Handberg EM, Zhou Q, Champion A, Pepine CJ, and Cohen JD. Larger BMI and Higher Systolic Blood Pressure Are Associated with Increased Risk of Newly Diagnosed Diabetes in Hypertensive Patients With Coronary Artery Disease: Findings from the International Verapamil SR-Trandolapril Study (INVEST). *Circulation*, 2006; 113(8):E351.
 36. Gong Y, Handberg EM, Gerhard T, **Cooper-DeHoff RM**, Johnson JA, Pepine CJ, Univ. FL, Gainesville, FL. Association of Systolic Blood Pressure (SBP) and Health Related Quality of Life in Patients with Coronary Artery Disease: An Analysis from the International Verapamil SR trandolapril Study (INVEST). *Circulation*, 2006;114 (18):II-2758.
 37. **Cooper-DeHoff RM**, McClure CK, Johnson B, Gulati M, Shaw LJ, Handberg EM, Zineh I, Kelsey S, Arnsdorf MF, Black HR, Bairey Merz CN, Pepine CJ. Adverse Cardiovascular Outcomes in Women with No Obstructive Coronary Artery Disease: A Report From The NHLBI-sponsored WISE Study and the St James WTH Project. *Circulation* 2006;114:II339.
 38. Shaw LJ, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, **Cooper-DeHoff RM**, Handberg EM, Berga S, Johnson BD, Bittner V, Rogers W, Pepine CJ, Bairey Merz CN. Cardiovascular Event-Free Survival in Post-Menopausal Women with Polycystic Ovary Syndrome: Results from the Women's Ischemia Syndrome Evaluation. Presented at AHA Scientific Sessions, Chicago, IL. Nov. 2006, *Circulation*, 2006; 114 (18).
 39. **Cooper-Dehoff RM**, Gerhard T, Gong Y, Handberg EM, Messerli FH, Pepine CJ, Blood Pressure < 120/80 mmHg is Risky in Elderly CAD Patients: Findings from the International Verapamil SR Trandolapril Study (INVEST) Abstract. *Circulation*. Feb. 2007. Vol. 115, No.8, e258, P168.

40. McClure CK, Johnson BD, Gulati M, **Cooper-DeHoff RM**, Shaw LS, Handberg E, Zineh I, Kelsey SF, Armsdorf M, Black H, Bairey CN, Pepine CJ. The Role of the Framingham Risk Score in Symptomatic Women: A Report from the NHLBI-Sponsored Women's Ischemia Study and the St. James Women Take Heart Project. *CVD Epidemiology and Prevention*. 2007, e253, P146.
41. Pacanowski MA, Gong Y, Langae Ty, **Cooper-DeHoff RM**, Schork NJ, Pepine CJ, Johnson JA. B2-adrenergic receptor polymorphisms and antihypertensive treatment outcomes in the INternational VERapamil SR/trandolapril STudy – GENETic Substudy (INVEST-GENES). *Clin. Pharmacol. Ther.* 2007; 81 (S1):S34. Presented as a poster at the American Society for Clinical Pharmacology and Therapeutics 108th Annual Meeting, Anaheim, CA. March 2007.
42. Schentrup AM, Nino G, Gong Y, Lima JJ, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. LTA4H variant confers drug therapy –dependant reduced risk of cardiovascular events in INVEST (International Verapamil SR/Trandolapril study) *Clin. Pharmacol Ther.* 2007; 81 (SI): S35.
43. Merz CB, Olson M, McClure C, Symons J, Sopko G, Kelsey S, Handberg-Thurmond E, Johnson BD, **Cooper-DeHoff R**, Sharaf B, Rogers W, and Pepine C. Chronic CAD: New Insights For Medical Therapy and Revascularization: Abstract 2450: A Randomized Controlled Trial of Low Dose Hormone Therapy on Myocardial Ischemia in Postmenopausal Women with No Obstructive Coronary Artery Disease: Results from the NHLBI-sponsored WISE Circulation, Oct 2007; 116: II 539.
44. Midwall S, Anderson RD, Johnson D, Handberg E, **Cooper-Dehoff R**, Smith K, Pepine C, In Women without Obstructive Coronary Artery Disease, Endothelial-Dependent and Non-Endothelial Dependent Coronary Reactivity Dysfunction are Associated with Different Types of Adverse Outcomes. The NHLBI Women's Ischemia Syndrome Evaluation (WISE) [2870]. ABS Oral Session AOP.45.2: Chronic CAD: Pathophysiology and Prognosis 2:30-2:45p #2870 - Tuesday, Nov. 6, 2007, AHA Circulation, Oct 2007; 116: II 639.
45. Bairey-Merz C, Olson M, McClure C, Symons J, Sopko G, Kelsey S, Handberg-Thurmond E, Johnson BD, **Cooper-DeHoff R**, Sharaf B, Rogers W, Pepine C. A Randomized Controlled Trial of Low Dose Hormone Therapy on Myocardial Ischemia in Postmenopausal Women with No Obstructive Coronary Artery Disease: Results from the NHLBI-sponsored WISE. ABS Oral Session AOP.45.1: Chronic CAD: New Insights for Medical Therapy and Revascularization 9:45-10a #2450 – Tuesday, Nov. 6, 2007, AHA.
46. Denardo SJ, Messerli FH, Gaxiola E, **Cooper-DeHoff RM**, Handberg EM, Champion A, Zhou Q, Pepine CJ. Association of “J-shaped” curves and coronary revascularization status: A substudy of the INVEST. ABS Oral Session AOP.96.4: Coronary Atherosclerosis and Events. 10:45-11a #3704 - Wednesday, Nov. 7, 2007, AHA
47. Pacanowski MA, Zineh I, Welder GJ, Adicks J, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. NOS3 polymorphisms do not associate with adverse clinical outcomes in elderly hypertensives with cardiovascular disease: Analysis of the INternational VERapamil SR-trandolapril STudy – GENETic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2008;83(S1):S83. Poster at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, April 2008.
48. Pacanowski MA, **Cooper-DeHoff RM**, Gong Y, Schork NJ, Pepine CJ, Johnson JA. Diabetes risk associated with β_1 -adrenergic receptor polymorphisms differs by antihypertensive drug therapy: Results from the INternational VERapamil SR/ trandolapril STudy – GENETic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2008;83(S1):S83. Poster at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, April 2008.
49. H.A. Navare, A.L. Beitelshes, Pharm D, MPH, Y. Gong, PhD, T.Y. Langae, PhD, **R.M.Cooper-Dehoff**, Pharm D, C.J.Pepine, MD, J.A.Johnson, Pharm D. Cacnaic Polymorphisms and Cardiovascular Outcomes in the International Verapamil

- SR/Trandolapril Study – Genetic Substudy (Invest-Genes). PT-10, Clinical Pharmacology and Therapeutics, 2008; 83 (S1):S4
50. Price ET, Martin MA, Pacanowski M, **Cooper-DeHoff RM**, Pepine C, Johnson JA, Zineh I. Liver X receptor- α gene variability and cardiovascular risk in the International Verapamil SR/Trandolapril Study – GENETic Substudy (INVEST-GENES). *Clinical Pharmacology & Therapeutics* (2008) 83, S66. doi:10.1038/sj.clpt.2008.44.
 51. Martin MA, Price ET, Pacanowski M, **Cooper-DeHoff RM**, Pepine C, Johnson JA, Zineh I. *MADD* variants and risk of cardiovascular events in the International Verapamil SR/Trandolapril Study – GENETic Substudy (INVEST-GENES). *Clinical Pharmacology & Therapeutics* (2008) 83, S82–S83. doi:10.1038/sj.clpt.2008.46.
 52. **Cooper-DeHoff RM**, Pepine CJ. Investigation of the early effects of ACE-I on Glucose Intolerance During Treatment with HCTZ in Patients with Hypertension and Metabolic Syndrome. Oral presentation at the Consortium for Southeastern Hypertension Control 15th Annual Scientific Sessions, 2008.
 53. **Cooper-DeHoff RM**, Pepine CJ. Dysglycemia During Treatment with HCTZ in patients with Hypertension and Metabolic Syndrome. Poster at the American Heart Association, Scientific Session, *Circulation*, 2008, 118:S889.
 54. Niu Y, Langae TY, Gong Y, Moss JI, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. DNA Variations in Voltage-gated Calcium Channel Beta 2 Subunit (CACNB2) Gene, Functional Consequences, and Association with Adverse Cardiovascular Outcomes in the International Verapamil SR-trandolapril Study-GENETic Substudy. Poster at the American Heart Association, Scientific Session, *Circulation*, 2008, 118:S885.
 55. **Cooper-DeHoff RM**, Gong Y, Marin J, Rosen A, Handberg EM, Johnson JA, Pepine CJ. Long-term Mortality Associated with New Onset Diabetes in Hypertensive CAD Patients Following Exposure to Antihypertensive medications: Findings from the International Verapamil SR/Trandolapril Study. *J Am Coll Cardiol* 2009, 0910-7:A224.
 56. Welder G, Price E, Duarte J, Handberg EM, Pepine CJ, **Cooper-DeHoff, RM**. PPAR γ Downregulation – A Novel Mechanism to Explain HCTZ Associated Dysglycemia in Patients with Hypertension and Metabolic Syndrome. Poster at the American Society of Hypertension, 24th Annual Scientific Meeting and Exposition, San Francisco, California, *J Clin Hypertension* 2009;11:A108.

PATENTS

US Patent No. 5,991,731

Title: Method and System for Interactive Prescription and Distribution of Prescriptions in Conducting Clinical Studies

UF Reference Number: 1682

INVITED JOURNAL REFEREE:

1. Psychosomatic Medicine
2. Journal of Human Hypertension
3. Clinical Cardiology
4. Circulation
5. Long Term Care Interface
6. British Journal of Clinical Pharmacology
7. Pharmacogenomics
8. Expert Review of Cardiovascular Therapy
9. Pharmacogenetics and Genomics
10. Lancet

EDITORIAL ACTIVITIES:

Editorial Board – Cardiology Today
Cardiovascular Pharmacology Section

Invited Quarterly Column – Cardiology Today, Pharmacology Consult

November 2006	FDA: Separate Ibuprofen and Aspirin
February 2007	Grapefruit – Drug Interaction: Important Considerations for Heart Disease Patients
May 2007	With OTC Simvastatin, U.K.'s Statin Prescriptions Down
August 2007	Taking Steps to Reduce NSAID Risks
November 2007	Patients Beware: Ways to minimize medication errors
February 2008	Genotype-guided warfarin dosing now a reality. An NIH study planned for this year will assess multiple outcomes related to warfarin safety and efficacy.
May 2008	Despite efforts, limited efficacy exists for dietary supplements, p.16
August 2008	Low-cost generic programs help make medication co-pays more affordable.

SELECTED INVITED PRESENTATIONS

1. Justifying, Implementing, and Financing Investigational Drug Services at Shands Hospital. Presented at the ASHP Midyear Meeting, Las Vegas, Nevada, December 1990.
2. Computerization of an Investigational Drug Service Data Base. Presented at the University Hospital Consortium's Technology Advancement Center Meeting, Chicago, Illinois, March 1991.
3. Formulary Management of Biotechnology Through a Subcommittee. Presented at the Biotechnology Institute, Charlotte, North Carolina, September 1993, August 1994.
4. Justifying, Implementing and Financing an Investigational Drug Service - an Update. Presented at the FSHP annual meeting, Orlando, Florida. August 19, 1994.
5. Participant in "Today in Cardiology" Roundtable. The Safety of Cox-2 Inhibitors in Patients with CHD. Anaheim, California, February 2001.
6. Managing Hypertension in CAD Patients: What Have the Clinical Trials Taught Us? Are the JNC VI guidelines being followed in the 21st Century? American College of Cardiology, Twenty-first annual perspectives on New Diagnostic and Therapeutic Techniques in Clinical Cardiology. January 27, 2002.
7. Managing Hypertension in Patients with CAD. Florida Society of Health System Pharmacists annual meeting, Jacksonville, Florida. November 10, 2002.
8. Hypertension: New Observations on Gender, Ethnicity, and Diabetes from INVEST. American College of Cardiology, Twenty-second annual perspectives on New Diagnostic and Therapeutic Techniques in Clinical Cardiology. January 24, 2003.
9. Managing Blood Pressure and Cardiovascular Risk in the Complex Patient – a Focus on the Guidelines and the Evidence. North Central Florida Society of Health System Pharmacists. March 31, 2004.
10. Pharmacologic Management of Hypertension. American College of Cardiology, March 11, 2006.
11. Women's Heart Health: An Update. Shands Women's Advantage, February 15, 2007
12. CAD, Inflammation and COX-2 Inhibitors. North Central Florida Society of Health System Pharmacists. March 14, 2007.
13. Women's Heart Disease – New Prevention Guidelines. Prime Time Institute, Gainesville, Florida. May 31, 2007.
14. Facilitating Investigator Initiated Research within the Cardiovascular Medicine Division, Cardiovascular Grand Rounds, Gainesville, Fl. August 23, 2007.

15. Cardiovascular Medications – an update. Oak Hammock Community, Gainesville, Florida. October 2, 2007
16. Hypertension: Evidence Based Treatments to Improve Patient Outcomes. American Health Resources, CVS Pharmacists, Ocala and Tampa, Florida. October 14 and 29, 2007.
17. Supplements: Where's the Evidence? American College of Cardiology Annual Scientific Sessions, Chicago, Illinois, March 2008.
18. Investigation of the early effects of ACE-I on Glucose Tolerance During Treatment with HCTZ in Patients with Hypertension and Metabolic Syndrome. Center for Pharmacogenomics Seminar, October 2008.
19. Antidepressant medications in the cardiovascular patient. American College of Cardiology Annual Scientific Sessions, Pharmacology Program, Orlando, Florida, March 2009.
20. Programs for getting and keeping your patients on their medications. American College of Cardiology Annual Scientific Sessions, Orlando, Florida, March 2009.
21. Brown Bag Supplements: Where's the Evidence? Preventive Cardiovascular Nurses Association Annual Meeting, Dallas, Texas. April 2009.